Back
to sessions
Sep 27
Poster Q & A
session DESCRIPTION
ASTRO's posters feature the latest scientific case studies, practice innovations and research from experts in the field of radiation oncology. In this session, in-person attendees will have the opportunity to ask poster presenters questions about their research.
This event is in-person only and will not be livestreamed or available onDemand.
Credits
| AMA PRA Category 1 Credits: | 0.00 |
| CAMPEP Credits: | 0.00 |
| MDCB Credits: | 0.00 |
Presentations
-
03:00pm - 04:00pm ET
Neurocognitive Outcomes in Patients with Brain Metastases: A Systematic Review of Past Findings and Future Directions
Speaker: Eugene Vaios, MD, MBA - Duke Cancer Institute, Durham -
03:00pm - 04:00pm ET
Enhanced Normal Tissue Sparing in Hippocampal-Avoidance Whole Brain Radiotherapy: A Dosimetric Study
Speaker: Racha Khodor, MD - American University of Beirut Medical Center, Beirut -
03:00pm - 04:00pm ETSpeaker: Arjun Vasan, MBA, BS - University of Texas Health Science Center at Houston, Houston
-
03:00pm - 04:00pm ET
Optimization of TTFields Delivery Using Segmentation-Based Treatment Planning with Head-Flexible Arrays
Speaker: Wenyin Shi, MD, PhD - Thomas Jefferson University, Philadelphia -
03:00pm - 04:00pm ETSpeaker: Kristin Redmond, MD, MPH, FASTRO - Johns Hopkins University, Baltimore
-
03:00pm - 04:00pm ET
Investigating Prognostic Value of Diffusion Weighted MRI for Patients with High Grade Glioma Undergoing PULSAR Reirradiation
Speaker: Gabrielle Gard, MD - Texas Health Resources Dallas, Dallas -
03:00pm - 04:00pm ETSpeaker: Jyotsna Natarajan, MD, BS - UNC Lineberger Comprehensive Cancer Center, Chapel Hill
-
03:00pm - 04:00pm ETSpeaker: Alexander Sasse, MD - UCSF Comprehensive Cancer Center, San Francisco
-
03:00pm - 04:00pm ET
Robotic-Arm Linear Accelerator Radiotherapy for Vestibular Schwannomas: A Single-Institution Experience
Speaker: Bartlomiej Goc, MD - Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Katowice -
03:00pm - 04:00pm ET
27 Gy in 3 Fractions Stereotactic Radiotherapy to Metastatic Brain Lesions Less Than 2 Cm: A Single Institution Experience
Speaker: Jimmy Sebaaly, MD - American University of Beirut, Beirut -
03:00pm - 04:00pm ET
Differential Redox Capacity In Pediatric and Adult High-Grade Gliomas Reveals Therapeutic Vulnerabilities
Speaker: Bogdan Buzdugan, BS - University of Iowa, Iowa City -
03:00pm - 04:00pm ET
N-Terminal Androgen Receptor Antagonists Offer Superior Tumor Suppression on Glioblastoma than C-Terminal Inhibitors
Speaker: Chi Zhang, MD, PhD - Mayo Clinic Arizona, Phoenix -
03:00pm - 04:00pm ETSpeaker: Wan-Jin Yeo, PhD - University of California, San Francisco, San Francisco
-
03:00pm - 04:00pm ET
Dosimetric Tolerances of the Brainstem and Anterior Optic Pathway to Re-Irradiation In Recurrent Gliomas
Speaker: Reza Djavadian, MD, PhD - University of Alabama at Birmingham, Birmingham -
03:00pm - 04:00pm ET
Peripheral Immune Profiles at 6-12 Weeks Post-Radiation, IDH Status, and MGMT Status or Other Clinical Characteristics in GBM Patients Treated with Chemoradiation
Speaker: Samuel Workman, MD - Johns Hopkins Hospital, Baltimore -
03:00pm - 04:00pm ET
Survival Prediction after Stereotactic Radiosurgery in Patients with Brain Metastases Using a Multimodal 3D MRI-Radiomics Deep Learning Model
Speaker: Yuming Jiang, MD - Wake Forest University School of Medicine, Winston-Salem -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Long-Term Outcomes and Late Effects of Surgery and Radiotherapy in Adult Intracranial Ependymoma Patients
Speaker: Olaf van de Langerijt, MD - Mass General Brigham Cancer Institute / Massachusetts General Hospital, Boston -
03:00pm - 04:00pm ET
Baseline and Time Dependent Predictors of Worsened Quality of Life, Symptoms of Depression, Anxiety, and Self-Reported Cognition: A Secondary Analysis of the ATHENA Trial
Speaker: Haley Perlow, MD - Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland -
03:00pm - 04:00pm ET
Tile-Based Radiation Therapy for Upfront Treatment of Grade 4 Gliomas in Patients =70 Years and/or Low KPS: Prospective Multi-Institutional Outcomes
Speaker: Matthew Peach, MD, MB, PhD - ECU Brody School of Medicine, Greenville -
03:00pm - 04:00pm ETSpeaker: Andrew Simpson, MD - UAB Radiation Oncology, Birmingham
-
03:00pm - 04:00pm ET
Impact of Complete GTV Inclusion within =110% Isodose on Local Control and Toxicity after Spine Reirradiation SBRT
Speaker: Ahmed Elguindy, MD - The Ohio State University James Cancer Hospital, Columbus -
03:00pm - 04:00pm ET
Long-Term Outcomes and Late Effects of Surgery and Radiotherapy in Adult Spinal and Myxopapillary Ependymoma Patients
Speaker: Olaf van de Langerijt, MD - Mass General Brigham Cancer Institute / Massachusetts General Hospital, Boston -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Clinical Context Improves Interpretation of ¹8F-Fluciclovine PET and Perfusion MRI for Distinguishing Radiation Necrosis from Tumor Recurrence Following Radiation Therapy for Brain Metastases
Speaker: Marshall Harrell, MD - The Ohio State University James Cancer Hospital, Columbus -
03:00pm - 04:00pm ET
Stereotactic Body Radiation Therapy for the Treatment of Spinal Chordomas - A Single Institutional Retrospective Review
Speaker: Grace Song, BA - Cleveland Clinic Foundation, Cleveland -
03:00pm - 04:00pm ETSpeaker: Vignesh Elangovan, BS - Ohio State University College of Medicine, Columbus
-
03:00pm - 04:00pm ETSpeaker: Jilcha Feyisa, MD, MPH - Dartmouth-Hitchcock Medical Center, Lebanon
-
03:00pm - 04:00pm ET
The Role of Tumor-Infiltrating Clonal Hematopoiesis and Frailty in Outcomes for Patients with IDH-Wildtype Glioblastoma
Speaker: Homayoun Ghaseminezhad, BS - University of Washington, Seattle -
03:00pm - 04:00pm ET
The Effect of Non-Enhancing Peri-Tumoral Hemorrhage on Local Control for Melanoma Brain Metastases Treated with Stereotactic Radiosurgery
Speaker: Muhammad Shohayeb, MD, MBChB - UPMC Cancer Center, Pittsburgh -
03:00pm - 04:00pm ET
Early Tumor Dynamics during Short-Course Fractionated SRT under Strict Imaging-to-Treatment Interval Control: Dosimetric Consequences and Implications for Adaptive Replanning
Speaker: Tsuyoshi Kudo, MS, RT - Department of Radiological Technology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, Hiroshima -
03:00pm - 04:00pm ET
PET Tracer-Guided Radiotherapy Dose Escalation in Treatment-Naïve Glioblastoma: A Systematic Review of Prospective Clinical Trials
Speaker: Sai Kumar Samala, MD, MBBS - University of California Los Angeles, Los Angeles -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ETSpeaker: Vikram Munlapudi, BS - Florida Atlantic University College of Medicine, Boca Raton
-
03:00pm - 04:00pm ET
Severe Primary Organ-Related Complications in Patients with De Novo Metastatic Cancer: Implications for Prophylactic Local Therapy
Speaker: Hefei Liu, MD, MS - University of Pennsylvania Radiation Oncology, Philadelphia -
03:00pm - 04:00pm ET
Neoadjuvant Radiotherapy Combined with Lenvatinib and Sintilimab in Patients with Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: An Open-Label, Single-Arm, Multicenter, Prospective Phase I Clinical Trial
Speaker: Bin Shu, - Hepatopancereatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing -
03:00pm - 04:00pm ET
A Prospective Pathological Study to Refine Radiotherapy CTV Delineation for ESCC After Neoadjuvant Chemoimmunotherapy
Speaker: Hang Yin, MD, PhD - Harbin Medical University Cancer Hospital, Harbin -
03:00pm - 04:00pm ET
Efficacy and Safety of Different Dose Patterns in Concurrent Integrated Radiotherapy for Esophageal Cancer: A Multicenter Real-World Study
Speaker: Wenbin Shen, MD - The Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Medium Dose of TPF Chemotherapy with Concurrent Radiotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma:A Prospective, Single Arm, Phase II Study (FUTURE-2)
Speaker: Xingwen Fan, MD, PhD - Fudan University Shanghai Cancer Center, Shanghai -
03:00pm - 04:00pm ET
Diffusion-Synthetic MRI for Privacy-Preserving Hybrid Training of Brain Tumor Auto-Segmentation in Radiotherapy
Speaker: Yu-Jen Wang, MD, PhD - FJUH, New Taipei City -
03:00pm - 04:00pm ET
Efficacy and Safety of Total Neoadjuvant Therapy in Elderly Patients with Locally Advanced Rectal Cancer: A Real-World Study
Speaker: Xiyang Ke, PhD - Peking University Health Science Center, Beijing -
03:00pm - 04:00pm ET
Optimal Sequencing of Immune Checkpoint Inhibitors with Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Cohort Study
Speaker: Wenbin Shen, MD - The Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Integrative Radiogenomic Analysis Identifies Imaging-Linked Molecular Subtypes and Drivers of Heterogeneity in Pancreatic Adenocarcinoma
Speaker: Dandan Zheng, PhD - University of Rochester, Rochester -
03:00pm - 04:00pm ETSpeaker: Giorgio Caturegli, MD - Yale University School of Medicine, New Haven
-
03:00pm - 04:00pm ET
Validation of Presacral Lymph Node Delineation in Non-Operative Treatment Strategies for Locally Advanced Rectal Cancer
Speaker: Keiko Murofushi, MD, PhD - Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku -
03:00pm - 04:00pm ET
Convergent Mechanisms of Immune Sensitization: scRNA-seq Reveals Shared TME Remodeling in Rectal Cancer Treated with Anti-PD-1 ± SCRT
Speaker: Yujun Liu, MD, PhD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai -
03:00pm - 04:00pm ET
CPI-613 (Devimistat) in Combination with Chemoradiation in Patients with Pancreatic Ductal Adenocarcinoma (PDAC): Results of the Phase I Clinical Trial
Speaker: Mandana Kamgar, MD - Medical College of Wisconsin, Milwaukee -
03:00pm - 04:00pm ET
Prognostic Value of Pre- and Post-Treatment PET-CT Metrics after Definitive Chemoradiation for Anal Canal Cancer
Speaker: Raksha Narasimhan, BS - University of Miami Miller School of Medicine, Miami -
03:00pm - 04:00pm ET
Optimizing Postoperative Adjuvant Strategies in Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy: A Multicenter Real-World Study
Speaker: Wenbin Shen, MD - The Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ETSpeaker: William Lee, BS - BC Cancer - Vancouver Centre, Vancouver
-
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Impact of Neoadjuvant Chemoradiation on Clinical Outcomes in Elderly Patients with Locally Advanced Rectal Cancer
Speaker: Tung Lin, MD - Chimei Medical Center, Tainan -
03:00pm - 04:00pm ET
Medium Dose of TPF Chemotherapy with Concurrent Radiotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Real-World Study
Speaker: Xingwen Fan, MD, PhD - Fudan University Shanghai Cancer Center, Shanghai -
03:00pm - 04:00pm ET
MRI-Based Radiomic Features for Predicting Treatment Response in Unresectable Hepatocellular Carcinoma Receiving Sequential Transarterial Chemoembolization and Stereotactic Body Radiotherapy Followed by Immunotherapy: An Exploratory Study
Speaker: Shugui Sheng, MS, MBBS - The University of Hong Kong, shatin -
03:00pm - 04:00pm ET
A Phase II Study of Fruquintinib Combined with Tislelizumab and Sequential Radiotherapy for Recurrent or Oligoprogressive Esophageal Squamous Cell Carcinoma
Speaker: Wenbin Shen, MD - The Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Hypofractionated Radiotherapy Combined with Nal-IRI + 5-FU/LV, Enlonstobart and Target Therapy in Locally Recurrent Rectal Cancer (NOVELTY-R): A Single-Arm Open-Label, Phase II Trial
Speaker: Ruiyan Wu, MD, PhD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai -
03:00pm - 04:00pm ET
Efficacy and Safety of Albumin-bound Docetaxel Plus Enlonstobart vs. Paclitaxel, Combined with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Unresectable Esophageal Squamous Carcinoma: Results from a Randomized Phase II Study
Speaker: Linlin Wang, MD, PhD - Shandong Cancer Hospital and Institute, Jinan -
03:00pm - 04:00pm ET
Serplulimab plus Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Multicenter, Phase I/II Trial (SCR-ESCC-02)
Speaker: Wen Yu, MD, PhD - Shanghai Chest Hospital Shanghai Jiao Tong University, Shanghai -
03:00pm - 04:00pm ETSpeaker: Kavita Sehrawat, MD - Baptist Health, Miami
-
03:00pm - 04:00pm ET
Outcomes of SRS for Isolated CNS Progression Among Patients with EGFR-Mutated NSCLC Receiving Osimertinib
Speaker: Matthew Riina, MD - Hospital of the University of Pennsylvania, Philadelphia -
03:00pm - 04:00pm ET
Analysis of Brain Metastases from Esophageal Cancer in the Era of Immunotherapy: A Single-Center Retrospective Study
Speaker: Qin Xiao, - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Shenzhen, Shenzhen -
03:00pm - 04:00pm ETSpeaker: Qiliang Peng, - Institute of Radiotherapy & Oncology,The Second Affiliated Hospital of Soochow University, Suzhou
-
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Stereotactic Central/Core Ablative Radiation Therapy (SCART) for Hepatic Tumors: A Single-Institution Case Series of 95 Patients
Speaker: Binguang Chen, MD - Junxin Oncology Institute, Foshan Fosun Chancheng Hospital, Foshan -
03:00pm - 04:00pm ETSpeaker: Frank Arturi, MEng - Memorial Sloan Kettering Cancer Center, New York
-
03:00pm - 04:00pm ET
A Novel Testicular Immobilization and Radiation Attenuation Device for Mitigating Testicular Dose During Radiotherapy for Colorectal and Anal Cancer Patients
Speaker: Toni Roth, PhD - Memorial Sloan Kettering Cancer Center, New York -
03:00pm - 04:00pm ET
Prognostic Value of Tumor Microenvironment Biomarkers and Tumor Regression Grading in Esophageal Squamous Cell Carcinoma Patients with Non-Pathological Complete Response (Non-pCR)
Speaker: Lihong Liu, PhD, MS - Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Hypofractionated FLASH Carbon Ion Radiotherapy Outperforms Standard Dose-Rate Treatment in Genetically Engineered Pancreatic Cancer Models: Impact of Adaptive Immune Responses
Speaker: Mahmoud Moustafa, DVM, PhD - German Cancer Research Center (DKFZ), Heidelberg -
03:00pm - 04:00pm ET
Advancing Multidisciplinary Protocols for Early Menopause after Pelvic Radiation for Locally Advanced Rectal Cancer in Young Patients
Speaker: Shari Bodofsky, MD - Yale Therapeutic Radiology, New Haven -
03:00pm - 04:00pm ET
ICON-RT: Intracranial Consolidation and Deferral of Radiation Therapy in Patients Receiving Approved CNS-Active Systemic Therapeutics
Speaker: Luke Pike, MD, DPhil - Memorial Sloan Kettering Cancer Center, New York -
03:00pm - 04:00pm ET
Impact of the Integrated Pathologic Score on Clinical Outcomes in Resected Esophageal Cancer following Neoadjuvant Chemoradiation
Speaker: Jin Ju Lee, MPH - University of South Florida Morsani College of Medicine, Tampa -
03:00pm - 04:00pm ETSpeaker: Jayme Leschly, BS - Icahn School of Medicine at Mount Sinai, New York
-
03:00pm - 04:00pm ETSpeaker: Travis Lambert, MD - Baylor College of Medicine, Houston
-
03:00pm - 04:00pm ET
Should Tumor-Draining Lymph Nodes be Spared from Irradiation during Immunotherapy? Insights from T Cell Analysis in Patients with Locally Advanced Rectal Cancer
Speaker: Shujuan Zhou, MD - Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai -
03:00pm - 04:00pm ETSpeaker: Julia Fricke, MD - University Hospital Basel, Basel
-
03:00pm - 04:00pm ET
A Nomogram Predicting Radiation-Related Lymphocyte Recovery and Its Prognostic Value for Survival in Locally Advanced Esophageal Squamous Cell Carcinoma
Speaker: Hongshan Ji, MD - The Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Prospective Evaluation of Early Cardiotoxicity in Patients Undergoing Photon or Proton Radiation Therapy for Locally-Advanced Distal Esophageal Cancer
Speaker: Nikita Gupta, BS - Georgetown University School of Medicine, Washington -
03:00pm - 04:00pm ET
Radical Surgery vs. Definitive Radiotherapy after Neoadjuvant Immunochemotherapy in Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
Speaker: Qiuying An, MD - Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Clinical Outcomes and Dose-Response after Repeat Spine Stereotactic Body Radiation Therapy for Local Failure
Speaker: Ian Messing, MD - The Hospital of the University of Pennsylvania, Philadelphia -
03:00pm - 04:00pm ET
Definitive Proton Beam Therapy for Oligometastatic Disease from Colorectal Cancer: A Single-Institution Retrospective Study Assessing the ESTRO-EORTC Classification
Speaker: Masaaki Goto, MD, PhD - University of Tsukuba, Tsukuba City 305-8575 -
03:00pm - 04:00pm ET
Comparative Local Control in Pancreatic Adenocarcinoma after Surgical Resection or Ablative Radiotherapy
Speaker: Keenan Robbins, MBBS, MPHS - Washington University School of Medicine in St. Louis, St. Louis -
03:00pm - 04:00pm ET
177Lu-edotreotide Absorbed Dose In Patients with Gastroenteropancreatic Neuroendocrine Tumors: Dosimetry Results from Compete
Speaker: Amir Iravani, MD, FRACP - University of California Los Angeles, Los Angeles -
03:00pm - 04:00pm ET
Accuracy of Restaging after TNT to Predict Final Treatment Response Among Locally Advanced Rectal Cancer Patients Receiving Short Course Radiation
Speaker: Kristine Bauer-Nilsen, MD - Virginia Commonwealth University Health System, Richmond -
03:00pm - 04:00pm ET
Pilot Study of Respiratory-Gated Stereotactic Body Radiation Therapy for Previously Treated Borderline Resectable, Unresectable, or Recurrent/Residual Adenocarcinoma of the Pancreas or Periampullary Region
Speaker: Arpan Prabhu, MD - Indiana University School of Medicine, Avon -
03:00pm - 04:00pm ET
A Prospective Pilot Trial of Multimodality Local Therapy Incorporating Histotripsy for Metastatic Pancreatic Ductal Adenocarcinoma
Speaker: Nikhil Thaker, MD, MBA, MHA - Capital Health Medical Center Hopewell, Pennington -
03:00pm - 04:00pm ET
Induction Chemotherapy Exposure as a Determinant of Local Control Independent of Radiation Modality in Pancreatic Cancer
Speaker: Ella Zhang, BS - Yale School of Medicine, New Haven -
03:00pm - 04:00pm ET
Association Between Rectal Cancer Magnetic Resonance Extramural Venous Invasion (mrEMVI) and Metachronous Liver and Lung Metastases
Speaker: Michelle Choi, BS - University of Alberta, Edmonton -
03:00pm - 04:00pm ET
Nimotuzumab Combined with Chemoradiotherapy vs. Chemoradiotherapy Alone in Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis of Survival and Safety Outcomes
Speaker: Lan Wang, MD, PhD - The Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Prognostic Factors for Progression-Free Survival after Resection and after Recurrence in IDH-Mutant Glioma
Speaker: Yen-Ting Liu, PhD Candidate - National Taiwan University, Taipei City -
03:00pm - 04:00pm ET
Assessment of IDH-Mutated Glioma Treatment Response to Long-Term Targeted Therapy by Longitudinal Tumor Volume Measurements
Speaker: Lindsey Ross, MD - Johns Hopkins Hospital, Baltimore -
03:00pm - 04:00pm ET
Induction Chemoimmunotherapy vs. Induction Chemotherapy followed by Definitive Radiotherapy in Esophageal Squamous Cell Carcinoma: An Observational Study on Efficacy and Factors Associated with Better Outcomes
Speaker: Xuejiao Ren, MD, PhD - Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Locally Recurrent Rectal Cancer: Is Omission of Elective Nodal Irradiation Feasible? — A Propensity Score-Matched Analysis in 186 Patients
Speaker: Feng-peng Wu, MD - Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Definitive Chemoradiotherapy vs. Esophagectomy In Patients with Clinical T1N0M0 Esophageal Squamous Cell Carcinoma: A Multi-Center, Retrospective Study from China
Speaker: Geng Xiang, - Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an -
03:00pm - 04:00pm ET
Association of Liver Elastography and Clinical Outcomes Among Patients with Hepatocellular Carcinoma Treated with Definitive External Beam Radiation Therapy
Speaker: Madhurya Reddy, MD, MBBS - Mayo Clinic, Rochester Radiation Oncology, Rochester -
03:00pm - 04:00pm ET
Phase II Trial of Locally Ablative Therapy for Oligoprogressive Gastrointestinal Malignancies: The LIVELONG Trial
Speaker: Jinger Sun, MD, PhD - University of California Davis, Sacramento -
03:00pm - 04:00pm ET
Does Regimen Selection Matter? Pathologic Complete Response across Four Contemporary Neoadjuvant Strategies in Rectal Cancer
Speaker: Andrea Rommal, MD, PhD - Northwell Health Center for Advanced Medicine, New Hyde Park -
03:00pm - 04:00pm ET
Comparative Study of Immunotherapy Combined with High-Dose vs. Standard-Dose Concurrent Chemoradiotherapy for Locally Advanced Cervical Esophageal Squamous Cell Carcinoma
Speaker: Can Wang, MD, PhD - Chongqing University Cancer Hospital, Shapingba -
03:00pm - 04:00pm ET
Evaluation of Intraoperative Cesium-131 Brachytherapy's Role in Local Control and Radionecrosis in Upfront Glioblastoma: A Case Series
Speaker: Colin Burns, BS, MPH - Virginia Tech Carilion School of Medicine, Roanoke -
03:00pm - 04:00pm ET
Preoperative Short-Course Radiotherapy Followed by Chemotherapy and PD-L1 Inhibitor for Locally Advanced Rectal Cancer: A Prospective Phase II Study
Speaker: Shanshan Bu, MD - First Affiliated Hospital of Zhengzhou University, zhengzhou -
03:00pm - 04:00pm ET
Exploring the Value of Additional Treatments Based on the Patterns of Failure After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma
Speaker: Jun Wang, MD, PhD, RT - Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Risk-Adapted Target Volume Design in FBCT-Guided Adaptive Stereotactic Radiotherapy for Pancreatic Cancer:Clinical Safety, Dosimetric and Spatial Analysis
Speaker: Shuyan Li, PhD - Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai -
03:00pm - 04:00pm ET
Heterogeneous Survival Impact of Induction Immunotherapy in Definitive Radiotherapy for Esophageal Squamous Cell Carcinoma: A Real-World Overlap Weighting Analysis
Speaker: Yan Luo, PhD - Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing -
03:00pm - 04:00pm ET
DECT-Derived Quantitative Parameters and Clinical Features for Predicting Prognosis in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
Speaker: Yongbin Cui, PhD - Shandong Cancer Hospital and Institute, Jinan -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Role of Postoperative Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoimmunotherapy: A Retrospective Propensity Score-Matched Study
Speaker: Li Li, - Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou -
03:00pm - 04:00pm ET
Effect of Combined Deep Hyperthermia Therapy on Radiation Proctitis in Patients with Rectal Cancer Receiving Neoadjuvant Chemoradiotherapy: A Single-Center Case-Control Study
Speaker: Chunbo Fan, - chongqing uninersity cancer hospital, chongqing -
03:00pm - 04:00pm ET
The Impact of Viral Etiology on External Beam Radiation Treatment for Hepatocellular Carcinoma Associated Portal Vein Tumor Thrombosis
Speaker: Donovan Brown, BS - UVA Department of Radiation Oncology, Charlottesville -
03:00pm - 04:00pm ET
Characterizing Molecular Radiosensitivity In Pituitary Neuroendocrine Tumors (PitNETs) Using Next-Generation Sequencing
Speaker: Archis Bhandarkar, MD - Mayo Clinic College of Medicine and Science Rochester, Rochester -
03:00pm - 04:00pm ET
Comparative Analysis of the Impact of Proton vs. Photon-Based Chemoradiation In Esophageal Cancer Patients on Peripheral Blood Lymphocyte Profile and Clonal Diversity Using Single Cell Combinational Sequencing
Speaker: Steven Lin, MD, PhD, FASTRO - The University of Texas MD Anderson Cancer Center, Houston -
03:00pm - 04:00pm ET
Primary and Complete Clinical Outcome Results from the TROG 17.03 Liver Ablative Radiotherapy with KIM (LARK) Trial
Speaker: Paul Keall, PhD, MS, BS, FASTRO - University of Sydney, Camperdown -
03:00pm - 04:00pm ET
Hypofractionated Radiotherapy Combined with Immunotherapy and Chemotherapy for Locally Recurrent Rectal Cancer (TORCH-R): A Prospective, Single-Arm, Two-Cohort, Phase II Trial
Speaker: Ruiyan Wu, MD, PhD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai -
03:00pm - 04:00pm ETSpeaker: Varintra Lander, MD, PhD - Washington University in St. Louis, St. Louis
-
03:00pm - 04:00pm ET
Impact of Diagnostic and Treatment Delays on Survival in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy: A Multi-Center Cohort Study
Speaker: Jiahao Zhu, MD - Suzhou Hospital affiliated to Nanjing Medical University, Wuxi -
03:00pm - 04:00pm ET
Safety of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Following Transarterial Radioembolization
Speaker: Nadin Badran, MD - Icahn School of Medicine at Mount Sinai, New York -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
An Integrative Multi-Omics Analysis of Biological and Clinical Impacts of Non-Histone Acetylation Enzymes and Substrates in Colon Cancer
Speaker: Jiahao Zhu, MD - Suzhou Hospital affiliated to Nanjing Medical University, Wuxi -
03:00pm - 04:00pm ET
Locoregional Treatment Outcomes of Hepatocellular Carcinoma Defined by Large Tumor Size or Macrovascular Invasion with Yttrium-90 Radioembolization and Stereotactic Body Radiation Therapy
Speaker: Abhiram Singh, - University of California Los Angeles, Los Angeles -
03:00pm - 04:00pm ET
Semiquantitative Analysis of DCE-MRI Perfusion Parameters in Spinal Metastases after RT: Treatment Response vs. Non-Response
Speaker: Matthew Arthur, BA - Harvard Medical School, Boston -
03:00pm - 04:00pm ET
To Explore the Efficacy and Safety of Neoadjuvant Chemoradiation Therapy in Locally Advanced Colon Cancer: A Systematic Review and Meta-Analysis
Speaker: Feng-peng Wu, MD - Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Breaking the Ceiling of Local Therapy: Evolutionary Trajectories and Systemic Bottlenecks In Anal Cancer from the 2D/3D to IMRT Era
Speaker: YangMei Zhou, MD - National Cancer Center/Cancer hospital & Shenzhen Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Shenzhen -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Benefit Analysis of Postoperative Adjuvant Therapy in Esophageal Squamous Cell Carcinoma Patients with Non-pCR or Non-MPR
Speaker: Likun Liu, MD, PhD - Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ETSpeaker: Khac Chien Tran, MD - Chang Gung University, Taoyuan City
-
03:00pm - 04:00pm ET
Outcomes Following Total Neoadjuvant Therapy with Radiation in Borderline Resectable Pancreatic Cancer
Speaker: Hannah Roberts, MD - Harvard Radiation Oncology Program, Boston -
03:00pm - 04:00pm ET
Longitudinal Outcomes and Toxicity after CNS Stereotactic Radiosurgery in Pediatric and AYA Patients
Speaker: Casey Hokanson, BA - University of Minnesota, Minneapolis -
03:00pm - 04:00pm ET
Real-World Survival Outcomes across Radiotherapy-Based Care Pathways for Esophageal Cancer: A Population-Based Study from Hong Kong CADRS
Speaker: Sijin Zhong, MD, PhD - The University of Hong Kong, Hong Kong -
03:00pm - 04:00pm ET
Efficacy of Thymosin a1 in Reducing Serious Adverse Events in Patients with Locally Advanced or Metastatic Abdominopelvic Carcinoma Treated with Concurrent Chemoradiotherapy
Speaker: Lining Chen, MD - Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical , Shenzhen -
03:00pm - 04:00pm ET
High-Resolution CBCT-Guided VMAT Lattice Radiotherapy for Bulky Hepatocellular Carcinoma: Early Tumor Regression as a Trigger for Adaptive Radiotherapy to Preserve OAR Sparing
Speaker: Yu-Wei Lin, MD, PhD, MS - Kaohsiung Veterans General Hospital, Kaohsiung -
03:00pm - 04:00pm ET
Initial Experience of Modern External Beam Dose Escalation in the Setting of Total Neoadjuvant Therapy for Rectal Cancer
Speaker: Gobind Gill, MD - University of Alabama at Birmingham, Birmingham -
03:00pm - 04:00pm ET
Impact of Gross Tumor Volume (GTV) and Effective Uniform Dose (EUD) on Clinical Outcomes after SBRT for Hepatocellular Carcinoma (HCC)
Speaker: Avinash Ramkissoon, MD, MPH - University of Pennsylvania Radiation Oncology, Philadelphia -
03:00pm - 04:00pm ET
Real-World Data: Postoperative Concurrent Chemorradiation for Resected Locally Advanced Gastric Cancer - Treatment Patterns and Risk Stratification
Speaker: Salvador Gutierrez Torres, MD - Instituto Nacional de Cancerologia, Mexico City -
03:00pm - 04:00pm ET
Impact of COVID-19 on Survival in Patients with Curative Stage I-III Sigmoid and Rectal Cancer: A Cohort Study of 765 Patients
Speaker: Ajra Secerov Ermenc, MD, PhD - Institute of Oncology Ljubljana, Ljubljana -
03:00pm - 04:00pm ET
Reirradiation for Primary Central Nervous System Tumors: A Retrospective Single- Institutional Review
Speaker: Aleena Abbasi, BS - Temple University School of Medicine, Philadelphia -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Dosimetric Evaluation of Ablative Stereotactic MR-Guided Adaptive Radiation Therapy for Anatomically Unfavorable Metastatic Colorectal Cancer
Speaker: Tatiana Bejarano, PhD, MS - Miami Cancer Institute: Baptist Health South Florida, Miami -
03:00pm - 04:00pm ET
Study Protocol of Neoadjuvant Concurrent Chemoradiotherapy Combined with CAPEOX and Immune Checkpoint Inhibitors for pMMR/MSS T4NanyM0 Colon Cancer: A Phase II, Prospective, Open-Label, Multi-Center, Randomized Controlled Trial(Neo-Color study)
Speaker: Feng-peng Wu, MD - Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Pretreatment Radiation Esophagitis Prediction Using Quantum Machine Learning in Esophageal Cancer Patients
Speaker: Congying Xie, MD, PhD - The First affiliated Hospital of Wenzhou Medical University, Wenzhou -
03:00pm - 04:00pm ET
CT-Based Deep Learning Radiomics in Predicting Disease-Free Survival and Overall Survival for Esophageal Squamous Cell Carcinoma Undergoing Radiotherapy: A Multicenter Study
Speaker: Xiance Jin, PhD - the 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou -
03:00pm - 04:00pm ET
Dosimetric Comparison of Intensity-Modulated Radiotherapy, Helical Tomotherapy, and Intensity-Modulated Radiotherapy Based on Orthogonal Dual-Layer Multileaf Collimator In Cervical Esophageal Cancer Patients with Definitive Chemoradiotherapy
Speaker: Jun Wang, MD, PhD, RT - Fourth Hospital of Hebei Medical University, Shijiazhuang -
03:00pm - 04:00pm ET
Impact of Neoadjuvant Chemotherapy vs. Chemoradiotherapy on Postoperative Complications and Surgical Outcomes in Locally Advanced Gastric Cancer: A Propensity Score-Matched Study
Speaker: Yifan Wang, - Cancer Hospital Chinese Academy of Medical Sciences, Beijing -
03:00pm - 04:00pm ET
Phase I Study of Radiation Dose Intensification with Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Speaker: Alden D'Souza, MD, MPHS - Washington University in St. Louis School of Medicine, St Louis -
03:00pm - 04:00pm ET
Treatment Mode and Prognostic Factors of Radiotherapy-Related Esophageal Fistula in Patients with Eesophageal Squamous Cell Carcinoma: A Retrospective Cohort Study
Speaker: Hanyu Si, MD, MB - Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang City -
03:00pm - 04:00pm ET
Incidence of Radiation Necrosis and Local Failure in Small Brain Metastases Treated with Single-Fraction vs. Multi-Fraction Stereotactic Radiosurgery
Speaker: Luke del Balzo, MD - Emory University Hospital, Atlanta -
03:00pm - 04:00pm ET
Precision Radiotherapy and Survival Benefit in Colorectal Liver Metastases: A Dual-Cohort Real-World Study
Speaker: Gang Ren, MD - Air Force Medical Center , Beijing -
03:00pm - 04:00pm ET
CT-Based Radiomic T-cell Inflamed Signature Refines Risk Stratification of Local Recurrence and Guides Immunotherapy Selection in Esophageal Cancer Treated with Definitive Chemoradiotherapy
Speaker: Jie Gong, PhD - Department of Radiation Oncology, Xijing Hospital, Air Force Medical University. Xi’an, China, Xi'an -
03:00pm - 04:00pm ET
The Optimal Neoadjuvant Modality in Locally Advanced Gastric Cancer in the Era of Immune-Drugs: A Multicenter Retrospective Analysis
Speaker: Quanming Liu, MD, PhD - Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing -
03:00pm - 04:00pm ET
Comparative Effectiveness and Safety of Systemic Therapy Plus Interventional Therapy with or without Radiotherapy in CNLC Stage IIIA Hepatocellular Carcinoma: A Retrospective Study
Speaker: Jiaxin Wang, MBBS - Shandong Provincial Key Laboratory of Precision Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical-Sciences, Jinan, Shandong,, Jinan -
03:00pm - 04:00pm ETSpeaker: Mauro Loi, MD, PhD - Azienda Ospedaliera Universitaria Careggi, Florence
-
03:00pm - 04:00pm ET
Clinical Course and Dose-Volume Analysis of Radiation-Induced Hypothyroidism after IMRT for Cervical Esophageal Cancer
Speaker: Ikuno Nishibuchi, MD, PhD - Department of Radiation Oncology, Hiroshima University, Hiroshima -
03:00pm - 04:00pm ET
Stereotactic Body Radiotherapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)- Prospective Study
Speaker: Reena Engineer, MD - Tata Memorial Centre, Mumbai -
03:00pm - 04:00pm ET
Incidence and Dosimetric Correlates of Radiation-Induced Lung Injury after Adjuvant Radiotherapy for Gastric Cancer
Speaker: Hatice Kubra Isik, MD - Marmara University Pendik Education and Research Hospital Radiation Oncology Clinic, Istanbul -
03:00pm - 04:00pm ET
Stereotactic Central/Core Ablative Radiation Therapy (SCART) for Recurrent Glioblastoma: A Multi-Center Case Series
Speaker: Qiuxia Lu, MD - Foshan Fosun ChanCheng Hospital, Foshan -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Ten-Year Outcomes of the Phase III ESO-Shanghai 1 Trial: Comparing Paclitaxel Plus Fluorouracil Group vs. Cisplatin Plus Fluorouracil Group in Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Speaker: Yun Chen, MD - Fudan University Shanghai Cancer Center, Shanghai -
03:00pm - 04:00pm ET
Impact of Tumor Length on Locoregional Control following Radical Concurrent Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Speaker: Radhika Patoriya, MD - Kiran Multi Super Speciality Hospital, Surat, Surat -
03:00pm - 04:00pm ET
Comparative Effectiveness of Intensity-Modulated Proton Therapy (IMPT), Passive-Scattering Proton Therapy (PSPT), and Volumetric-Modulated Arc Therapy (VMAT) on Radiation-Induced Lymphopenia (RIL) in Esophageal Cancer (EC) Chemoradiotherapy
Speaker: Zongsheng Hu, PhD - University of Pennsylvania, Philadelphia -
03:00pm - 04:00pm ET
Outcomes Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Single Institution Experience
Speaker: Andrew Skipper, MD - Duke University Health System, Durham -
03:00pm - 04:00pm ET
Selective Benefit of Adjuvant Chemoradiotherapy after Inadequate D2 Dissection in Gastric Cancer: A Multicenter Retrospective Comparative Study
Speaker: Altaf Hossain, MD, MBBS - Directorate General of Health Service, Dhaka -
03:00pm - 04:00pm ETSpeaker: Dashan Ai, MD - Fudan University Shanghai Cancer Center, Shanghai
-
03:00pm - 04:00pm ETSpeaker: Danielle Burner, BS - Duke University, Durham
-
03:00pm - 04:00pm ET
Are Late Complications Emerging in Patients Treated with Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Pancreatic Cancer?
Speaker: Sarah Pilarski, BS - Michigan State University College of Human Medicine, East Lansing -
03:00pm - 04:00pm ET
Discrepancies In Pancreatic Cancer Genomic Landscape between the Cancer Genome Atlas and a Large Single-Institution Database
Speaker: Susannah Ellsworth, MD - University of Pittsburgh Cancer Centers, Pittsburgh -
03:00pm - 04:00pm ET
Risk Factors for Treatment-Related Effects in Brainstem Metastases Following Stereotactic Radiosurgery
Speaker: Darien Colson-Fearon, MD, MPH - MD Anderson Cancer Center, Houston -
03:00pm - 04:00pm ETSpeaker: Alice Silberstein, MD - Harvard Radiation Oncology Program, Boston
-
03:00pm - 04:00pm ET
Optimal Central Hepatobiliary Tract Volumetric Expansion to Predict Adverse Events after MRI-Guided Liver SBRT: An NTCP Analysis
Speaker: Jodi Goldman, MD - UCLA Radiation Oncology, Los Angeles -
03:00pm - 04:00pm ETSpeaker: Caroline Dobeson, MB, ChB - The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne
-
03:00pm - 04:00pm ET
Ablative Stereotactic MR-Guided Adaptive Radiation Therapy for Anatomically Unfavorable Metastatic Colorectal Cancer
Speaker: Kavita Sehrawat, MD - Baptist Health, Miami -
03:00pm - 04:00pm ET
CBCT Based Online Adaptive Radiotherapy (oART) of Locally Advanced Rectal Cancer (LARC) - First Clinical Experience and Dosimetry Benefits: A Prospective Observational Study
Speaker: Natalia Wisniewska, MD - Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw -
03:00pm - 04:00pm ET
Radiation Enteritis Requiring Hospitalization: National Trends, GI Management Patterns and Disparities
Speaker: Jeril Lasington, MD, MS, MBBS - New York Medical College at St.Mary's and St. Clare's, Denville -
03:00pm - 04:00pm ET
Differences In Sociodemographic and Treatment Patterns By Medicaid Enrollment Among Patients with Hepatobiliary Cancers
Speaker: Jennifer Chiang, MD, MS - Stanford Health Care, Stanford -
03:00pm - 04:00pm ET
Separation Surgery Followed by Stereotactic Body Radiotherapy (24Gy in Two Fractions) for Metastatic Epidural Spinal Cord Compression: A Retrospective Study of 120 Patients
Speaker: Kentaro Taguchi, MD - Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo -
03:00pm - 04:00pm ET
Association of Serum Metabolomic Signatures with Survival in Pancreatic Cancer Patients Undergoing Neoadjuvant Therapy
Speaker: Diya Choudhary, BS - University of Texas MD Anderson Cancer Center, Houston -
03:00pm - 04:00pm ET
Early Experience and Impact of Curative-Intent Treatment on Esophageal Cancer Outcomes in a Newly Established Tertiary Cancer Centre in North India
Speaker: Ajay Choubey, MBBS, DNB - Homi Bhabha Cancer Hospital and Research Centre, varanasi -
03:00pm - 04:00pm ET
Radiation Therapy Utilization and Survival Disparities in Locally Advanced Pancreatic Cancer by Race, Income and Geography: A Population-Based Analysis
Speaker: Jeril Lasington, MD, MS, MBBS - New York Medical College at St.Mary's and St. Clare's, Denville -
03:00pm - 04:00pm ET
Trends in Neoadjuvant Radiation Therapy Utilization and Survival Outcomes for Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy: A SEER Population-Based Analysis
Speaker: Jeril Lasington, MD, MS, MBBS - New York Medical College at St.Mary's and St. Clare's, Denville -
03:00pm - 04:00pm ET
The Effects of Irradiating the Triangle Volume for Locally Advanced and Borderline Resectable Pancreatic Adenocarcinoma in Patients with Poor Response to Chemotherapy
Speaker: Shuchi Sehgal, DO - Johns Hopkins Medicine, Baltimore -
03:00pm - 04:00pm ETSpeaker: Rasika Sangle, MD, MBBS - Tata Memorial Hospital, Mumbai
-
03:00pm - 04:00pm ET
Efficacy of Combined Chemoradiotherapy and Immunotherapy vs. Chemoradiotherapy Alone in Patients Aged 70 Years and Older With Locally Advanced or Oligometastatic Esophageal Cancer
Speaker: Yujie Wang, - Affiliated Cancer Hospital of Shandong First Medical University, Shandong Cancer Hospital and Institute, Jinan -
03:00pm - 04:00pm ET
Multi-Omics Prediction of Radiosensitivity in Pancreatic Adenocarcinoma: A Machine Learning Radiogenomics Model
Speaker: Jeril Lasington, MD, MS, MBBS - New York Medical College at St.Mary's and St. Clare's, Denville -
03:00pm - 04:00pm ET
Impact of Aggressive Treatment on Outcomes in IDH-Wildtype Glioblastoma Patients with Leptomeningeal Dissemination (KROG 24-07)
Speaker: In Ah Kim, MD, PhD - Seoul National University Bundang Hospital, Seongnamsi -
03:00pm - 04:00pm ET
Contrast-Enhanced Adaptive Stereotactic Body Radiotherapy (SBRT) for Multiple Hepatic Lesions with One Isocenter Using the Ethos Platform
Speaker: Kim Vo, DO, MS - City of Hope Comprehensive Cancer Center, Duarte -
03:00pm - 04:00pm ET
A Phase II Trial of the Efficacy and Safety of Short Course Radiation Therapy and Long Course Chemo-Radiation Therapy with and without Radioprotector as Part of Total Neoadjuvant Therapy in Locally Advanced Rectal Adenocarcinoma
Speaker: Chi Lin, MD, PhD, MS - University of Nebraska Medical Center, Omaha -
03:00pm - 04:00pm ET
Weight Loss during Neoadjuvant Chemoradiotherapy and Survival after Esophagectomy for Locally Advanced Esophageal Squamous Cell Carcinoma
Speaker: Guiyu Huang, MSN, RN - Sichuan Cancer Hospital, Chengdu -
03:00pm - 04:00pm ET
Impact of Carbon Fiber vs. Titanium Spinal Instrumentation on Post-Operative Stereotactic Body Radiation Therapy Dose Delivery to Target Volumes and Critical Structures
Speaker: Dylan Ross, MD - Johns Hopkins Hospital, Baltimore -
03:00pm - 04:00pm ET
Hypofractionated Four-Fraction SRS Regimen for Pituitary Adenomas and Meningiomas Abutting or Overlapping the Optic Apparatus: Clinical Outcomes and Proposed Optic Abutment Grading
Speaker: Celia Reynolds, MD - Atrium Health Wake Forest Baptist, Lexington -
03:00pm - 04:00pm ETSpeaker: Ryan Ko, MD - MD Anderson Cancer Center, Houston
-
03:00pm - 04:00pm ET
The Presentation of Leptomeningeal Disease by Breast Cancer Subtype and Potential Implications for Surveillance Brain MRIs
Speaker: Jennifer Barranco, BS - University of South Florida College of Medicine, Tampa -
03:00pm - 04:00pm ETSpeaker: Neil Mookerjee, MD - Thomas Jefferson University, Philadelphia
-
03:00pm - 04:00pm ETSpeaker: Mitchell Parker, MD, PhD - Memorial Sloan Kettering Cancer Center, New York
-
03:00pm - 04:00pm ETSpeaker: Maleeha Qazi, MD, PhD - University of Toronto, Toronto
-
03:00pm - 04:00pm ET
Single Radiosurgery Prescription Increases Efficiency without Clinical Detriment in Patients with Multiple Brain Metastases of Varying Sizes: A Retrospective Review of Zero Margin, Frameless, Single-Isocenter, Multitarget Radiosurgery
Speaker: Luke Moradi, MD - University of Alabama at Birmingham, Birmingham -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
¹8F Fluciclovine PET In Postoperative Target Delineation and Recurrence Detection In Resected Brain Metastasis: Pre-Planned Analysis of a Prospective Trial
Speaker: Hanan Hassan, MD, MBBS - Larkin Community Hospital, Longmont -
03:00pm - 04:00pm ETSpeaker: Faith Ryu, BA - Dartmouth Geisel School of Medicine, Lebanon
-
03:00pm - 04:00pm ET
Automated Clinical Target Volume to Improve Efficiency of Contouring for Spine Metastasis Patients Treated with Stereotactic Body Radiation Therapy
Speaker: Gregory Buti, PhD - Massachusetts General Hospital, Winchester -
03:00pm - 04:00pm ET
Radiation Effects in Corpus Callosum and Processing Speed Specificity: Implications for Cognitive Sparing
Speaker: Atul Saha, BS - UCSD School of Medicine, La Jolla -
03:00pm - 04:00pm ET
Clinical Study of Hypofractionated Radiotherapy Combined with Temozolomide and Bevacizumab In the Treatment of Newly Diagnosed Postoperative Glioblastoma
Speaker: Can Wang, MD, PhD - Chongqing University Cancer Hospital, Shapingba -
03:00pm - 04:00pm ET
Promising Outcomes of Stereotactic Radiotherapy for Rare Extracranial Schwannomas: A Single-Institution Analysis of Pain and Local Stability
Speaker: Anna Misiorowska-Golosz, MD - Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice -
03:00pm - 04:00pm ET
Dose-Escalated WBRT Independently Improves Survival In NSCLC Leptomeningeal Metastases: A Multimodal Analysis of Local and Systemic Therapies
Speaker: Shoaib Bashir, MD, PhD - Guangdong Sanjiu Brain Hospital, Guangzhou -
03:00pm - 04:00pm ET
Understanding the Incidence and Mortality of Brain Tumors through the Lens of Socioeconomic Development: A Global Analysis
Speaker: Shivani Nagamalla, BS - New York Medical College, Valhalla -
03:00pm - 04:00pm ET
Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series
Speaker: Lauren Linkowski, MD, BS - Hospital of the University of Pennsylvania, Philadelphia -
03:00pm - 04:00pm ET
The Role of Lesion-Specific V12Gy as a Novel Predictor of Radionecrosis Following SRS in Multi-Metastasis Cases
Speaker: Carina Sclafani, BA - University of Pittsburgh School of Medicine, Pittsburgh -
03:00pm - 04:00pm ET
A Pilot Study for CT-Based Online Adaptive Radiotherapy in Patients with Newly Diagnosed High-Grade Glioma
Speaker: Kayla Daniell, MD - Columbia University Irving Medical Center, New York -
03:00pm - 04:00pm ET
Survival after Stereotactic Radiosurgery for Brain Metastases among Lung Cancer Patients Who Later Developed Leptomeningeal Disease
Speaker: Cindy Liu, BS - NYU Grossman School of Medicine, New York -
03:00pm - 04:00pm ET
Survival and CNS Disease Control among Patients with HER2 Low vs. HER2 Positive Metastatic Breast Cancer with Brain Metastases Treated with SRS
Speaker: Ian Messing, MD - The Hospital of the University of Pennsylvania, Philadelphia -
03:00pm - 04:00pm ET
Smart Surveillance: Digital Mobility Biomarkers from Wearables and Smartphones for Early Detection of Brain Metastases in High-Risk Cancer Patients
Speaker: Kathryn Tsai, BS - Carle Illinois College of Medicine, Urbana -
03:00pm - 04:00pm ETSpeaker: Michael Gribble, MD - UCSF Comprehensive Cancer Center, San Francisco
-
03:00pm - 04:00pm ET
BLAZE (Boosted Lesion Ablative Zone Escalation) in Spinal Radiation Therapy: A Systematic Review and Meta-Analysis of Safety and Efficacy
Speaker: Alexis Narvaez Rojas, MD - Maimonides Medical Center, New York -
03:00pm - 04:00pm ETSpeaker: Shrishti Shrivastava, BS - Rush Medical College of Rush University, Chicago
-
03:00pm - 04:00pm ETSpeaker: Drishti Panse, MD, BS - Icahn School of Medicine at Mount Sinai, New York
-
03:00pm - 04:00pm ET
First Clinical Experience of Adaptive MRI-Guided Radiotherapy for Midline Glioma: CTV Dynamics in H3K27M-Altered Tumors
Speaker: Haruo Inokuchi, MD, PhD - osaka metropolitan university, Osaka-city -
03:00pm - 04:00pm ET
Tumor Control Probability Modeling of Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for Patients with Brainstem Metastases
Speaker: Jiwen Xu, MD - Tianjin Medical University Cancer Institute and Hospital, Tianjin -
03:00pm - 04:00pm ET
Modeling Pre-Operative Spine Stereotactic Body Radiation Therapy (SBRT) for Treatment of Metastatic Spinal Disease Requiring Spinal Decompression Surgery
Speaker: Julia Hall, BA - Loyola University Chicago Stritch School of Medicine, Maywood -
03:00pm - 04:00pm ET
Cranial Radiotherapy and Local Fraction Dose for Treatment-Naive EGFR-Mutant NSCLC with Brain Metastases on First-Line-3rd-Generation TKIs, Stratified by Lung-molGPA: A Multi-Center Retrospective Analysis
Speaker: Guangchuan Deng, - Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,, Ji Nan -
03:00pm - 04:00pm ET
A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) from Small Cell Lung Cancer (SCLC)
Speaker: Kathryn Hockemeyer, MD, PhD - Memorial Sloan Kettering Cancer Center, New York -
03:00pm - 04:00pm ETSpeaker: Yue Gao, - Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an
-
03:00pm - 04:00pm ETSpeaker: Yexiang Lin, - Wuhan Union Hospital, Wuhan
-
03:00pm - 04:00pm ET
Evaluating Stereotactic Radiosurgery as an Alternative to Whole Brain Radiotherapy for NSCLC Patients with 15 or More Brain Metastases
Speaker: Wen-Chi Yang, MD, PhD - National Taiwan University Hospital, Taipei -
03:00pm - 04:00pm ET
Clinical Outcomes of Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy for Brain Metastases
Speaker: Lucas Pari Mitre, MD - UT Southwestern Medical Center, Dallas -
03:00pm - 04:00pm ET
Retrospective Analysis of Intra-Fraction Motion and Treatment Time during Mask-Based Gamma Knife Radiosurgery
Speaker: Fereshteh Talebi, MD - Harbor-UCLA Medical Center, Los Angeles -
03:00pm - 04:00pm ETSpeaker: Yildiz Yukselen Guney, MD, PhD - Ankara Etlik City Hospital, Ankara
-
03:00pm - 04:00pm ETSpeaker: Laith Samhouri, MD, MHBA - Jordan University of Science and Technology, Irbid
-
03:00pm - 04:00pm ET
VMAT Craniospinal Irradiation for Leptomeningeal Disease - Coverage and OAR Tradeoffs with Bone Marrow Sparing Maximization
Speaker: Jiayi Liu, MS - UCI Health Chao Family Comprehensive Cancer Center, Orange -
03:00pm - 04:00pm ET
Predictors of Outcomes Following Proton Craniospinal Irradiation for Solid Tumor Leptomeningeal Metastasis
Speaker: Eyub Yasar Akdemir, MD - Baptist Health, Miami -
03:00pm - 04:00pm ET
Multi-Institutional Analysis of Dose and Factors Associated with All Cause Morbidity after Stereotactic Radiotherapy for Intact Melanoma Brain Metastases
Speaker: Owen Snyder, BA - University of Cincinnati College of Medicine, Cincinnati -
03:00pm - 04:00pm ET
External Validation of a Spine SBRT Pain Flare Risk Stratification Model: A Foundation for aFuture Alliance Trial
Speaker: Khaled Dibs, MD - Ohio State University Wexner Medical Center, Columbus -
03:00pm - 04:00pm ET
Predictors of Toxicity after Re-Irradiation for Recurrent Grade 3-4 Glioma: A Multi-Institutional Analysis
Speaker: John Petersen, DO - Wake Forest Baptist Medical Center, Winston Salem -
03:00pm - 04:00pm ET
Association of Changes in Circulating Immune Cells With Survival in GBM Patients Treated With Chemoradiation
Speaker: Samuel Workman, MD - Johns Hopkins Hospital, Baltimore -
03:00pm - 04:00pm ET
Preoperative Circulating Cell-Free DNA as a Prognostic Biomarker in Surgically Treated Spinal Metastatic Disease
Speaker: Khaled Dibs, MD - Ohio State University Wexner Medical Center, Columbus -
03:00pm - 04:00pm ET
Safety and Local Control of 5-Aminolevulinic Acid Fluorescence-Guided Surgery Combined with Cesium-131 Brachytherapy for Glioblastoma: A Matched-Pair Analysis
Speaker: Michael Chodakiewitz, MD - Tufts Medical Center | Beth Israel Deaconess Medical Center, Boston -
03:00pm - 04:00pm ET
Comparative Outcomes of Preoperative vs. Postoperative Stereotactic Radiosurgery for Resected Brain Metastases: A Meta-Analysis (COPPER-BrM)
Speaker: Andre Gouveia, MD, MBA - McMaster University, Hamilton -
03:00pm - 04:00pm ET
Evaluating Tumor Growth and Dosimetric Under-Coverage Due to Delays in Brain Metastasis Radiosurgery
Speaker: Eyub Yasar Akdemir, MD - Baptist Health, Miami -
03:00pm - 04:00pm ET
Treated and Replanned Hippocampal Doses in Patients Receiving Photon vs. Proton RT for Favorable Grade 2-3 IDHmt Gliomas
Speaker: Alyssa Davis, BS - University of Cincinnati, Cincinnati -
03:00pm - 04:00pm ET
Radiosurgery Outcomes for Patients with Significant Intra-Cranial Disease Burden with =50 Brain Metastases
Speaker: Anna Chung, BS - University of Texas Southwestern Medical Center, Dallas -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Treatment Related Lymphopenia and Associated Outcomes in a Large Cohort Treated with Radiation/TMZ Incorporating Brain Dosimetric Analysis
Speaker: Alexander Ho, MD - Northwestern Memorial Hospital, Chicago -
03:00pm - 04:00pm ET
Diagnostic Performance of Treatment Response Assessment Maps In Detecting Tumor Recurrence vs. Adverse Radiation Effect after Brain Radiation
Speaker: Xi Cao, MD - Corewell Health William Beaumont University Hospital, Royal Oak -
03:00pm - 04:00pm ET
Fractionated Stereotactic Radiosurgery for Brain Metastases: Effect of Lesion Size and Dose on Local Failure and Radionecrosis
Speaker: Daniel Schep, MD, MS - Juravinski Cancer Centre, Hamilton -
03:00pm - 04:00pm ETSpeaker: Alexander Ho, MD - Northwestern Memorial Hospital, Chicago
-
03:00pm - 04:00pm ETSpeaker: Melanie Berger, MD - Hospital of the University of Pennsylvania, Philadelphia
-
03:00pm - 04:00pm ET
Gliofocus: A Global, Open-Label, Randomized Phase 3 Study Comparing Niraparib with Temozolomide in Newly Diagnosed MGMT-Unmethylated Glioblastoma
Speaker: William Kennedy, MD - Barrow Neurological Institute, Phoenix -
03:00pm - 04:00pm ETSpeaker: Sravya Koduri, MD, BS - NYU Langone Health, New York
-
03:00pm - 04:00pm ET
Early MRI Radiomics-Based Triage Model Predicts Response and Survival after Bevacizumab in Recurrent Glioblastoma
Speaker: Weir Chiang You, MD, PhD - Taichung Veterans General Hospital, Taichung -
03:00pm - 04:00pm ET
Radiosensitization and Active Antitumor Effect of Antibody-Drug Conjugates on Brain Metastases after Whole Brain Radiation
Speaker: Yao Yu, MD - Memorial Sloan Kettering Cancer Center, New York -
03:00pm - 04:00pm ET
Time to Development of Leptomeningeal Disease (LMD) among Metastatic Cancer Patients Who Undergo Stereotactic Radiosurgery (SRS)
Speaker: Ananya Jambhale, BS - NYU Grossman School of Medicine, New York -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Machine Learning-Based Clinico-Radiomic Model for Predicting Brain Metastasis Velocity after Stereotactic Radiosurgery: A Multi-Institutional Validation Study
Speaker: Cheng-Shien Shieh, MD - Taipei Medical University Hospital, Taipei 10449 -
03:00pm - 04:00pm ET
Introduce the First Dynamic-CSI Technique: Enhancing Delivery Efficiency with Improved Organ at Risk Dose Sparing
Speaker: Jun Liao, MD - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Shenzhen -
03:00pm - 04:00pm ETSpeaker: Lamees El Nihum, MD, MEng - Fox Chase Cancer Center, Philadelphia
-
03:00pm - 04:00pm ET
Investigation of the Subcutaneous-to-Visceral Fat Ratio as a Prognostic Biomarker for Survival after Ablative MR-Guided Adaptive Radiotherapy for Pancreatic Cancer
Speaker: Naseem Ud Din, PhD - Miami Cancer Institute: Baptist Health South Florida, Miami -
03:00pm - 04:00pm ET
Volumetric Changes in High-Grade IDH Mutant Diffuse Gliomas Treated with Reduced Margin Adaptive Intensity Modulated Proton Therapy
Speaker: Rahat Malhotra, MD, Resident - Tata Memorial Hospital, Mumbai -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Four-year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Chemoradiotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Study
Speaker: Xiaoli Zheng, MD - The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Beijing -
03:00pm - 04:00pm ET
Survival Outcomes of Adjuvant Immunotherapy after Neoadjuvant Chemoimmunotherapy Followed by Esophagectomy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
Speaker: Xiaoli Zheng, MD - The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Beijing -
03:00pm - 04:00pm ET
Comparative Efficacy of Whole-Brain Radiotherapy Combined with EGFR-TKI vs. EGFR-TKI Monotherapy in EGFR-Mutant NSCLC with Leptomeningeal Metastasis
Speaker: Xiaoli Zheng, MD - The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Beijing -
03:00pm - 04:00pm ET
Efficacy and Safety of Fractionated Stereotactic Radiosurgery for the Treatment of Large Intracranial Arteriovenous Malformations
Speaker: Eugene Vaios, MD, MBA - Duke Cancer Institute, Durham -
03:00pm - 04:00pm ET
Impact of Post-SABR Lymphopenia on Outcomes of SABR Combined with ICI or TKI in Extrahepatic Metastatic Hepatocellular Carcinoma
Speaker: Nalee Kim, MD, PhD - Samsung Medical Center, seoul -
03:00pm - 04:00pm ET
Longitudinal Single-Cell RNA Sequencing Highlights Distinct Tumor Microenvironment Dynamics between Very Early-Onset and Late-Onset Locally Advanced Rectal Cancer Receiving Immunotherapy-Based Total Neoadjuvant Therapy
Speaker: Luoxi He, BS - Fudan University Shanghai Cancer Center, Shanghai -
03:00pm - 04:00pm ET
Integrated Multidomain Prognostic Factors for Disease-Free and Overall Survival After Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Speaker: Firas Almomen, MBBS - King Saud University Medical City, Riyadh -
03:00pm - 04:00pm ET
Role of SBRT in the Management of Metastatic Colorectal Cancer: Oncologic Outcomes and Prognostic Factors from a Single-Institution Experience
Speaker: Firas Almomen, MBBS - King Saud University Medical City, Riyadh -
03:00pm - 04:00pm ET
Evaluation of Single- vs. Dual-Arc Dynamic Collimator VMAT for Stereotactic Spine Radiosurgery Using a Modified Modulation Complexity Metric
Speaker: Shu-Fan Wang, MS - National Yang Ming Chiao Tung University, Tinan City -
03:00pm - 04:00pm ETSpeaker: Yurika Tarui, - Johns Hopkins University, Baltimore
-
03:00pm - 04:00pm ET
Radiotherapy plus Chemoimmunotherapy Followed by Surgery for Gastric Cancer with Limited Lymph Node Metastases: Preliminary Results from the MIRACLE-G Study
Speaker: Fan Xia, MD, PhD - Fudan University Shanghai Cancer Center, Shanghai -
03:00pm - 04:00pm ET
Evaluating AI Models with MRI Radiomics and Deep Learning Features vs. Clinical Variables for Predicting Extended Survival in Newly Diagnosed Glioblastoma
Speaker: Wentao Wang, PhD, MS - Thomas Jefferson University, Philadelphia -
03:00pm - 04:00pm ETSpeaker: Chan Woo Wee, MD, PhD - Yonsei Cancer Center, Yonsei University College of Medicine, Seoul
-
03:00pm - 04:00pm ET
Why Two are Better than One: Combined Modality Salvage Therapy's Effects on Outcomes in Recurrent Glioblastoma
Speaker: Benson Wan, MD, BS - McGill University, Montreal -
03:00pm - 04:00pm ET
Neoadjuvant Short-Course Radiotherapy Combined with Immunochemotherapy vs. Chemotherapy Alone in pMMR Colon Cancers: The TORCH-C Randomized Phase 2 Clinical Trial
Speaker: Fan Xia, MD, PhD - Fudan University Shanghai Cancer Center, Shanghai -
03:00pm - 04:00pm ET
-
03:00pm - 04:00pm ET
Cochlear Dose as a Predictor of Hearing Preservation in Patients with Vestibular Schwannoma Treated with Fractionated Stereotactic Radiotherapy
Speaker: Rafael Hernandez, BS - Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia -
03:00pm - 04:00pm ET
Regulatory T Cell-Enriched Immune Trajectories during Radiotherapy Associate with Reduced PFS and Diverge during Photon vs. Proton Therapy
Speaker: Jacob Smith, - Vaccine & Immunotherapy Center, Massachusetts General Hospital & Harvard Medical School, Charlestown -
03:00pm - 04:00pm ET
Mitochondrial Proteins as Therapeutic Targets in Hepatocellular Carcinoma: Evidence from Mendelian Randomization Analysis
Speaker: Ye Hong, DO - Chongqing University Cancer Hospital, Chongqing -
03:00pm - 04:00pm ET
Longitudinal Radiomic Feature Instability in Auto-Segmented Gastrointestinal Organs-at-Risk Identifies Distinct Patient Phenotypes During Abdominal Radiotherapy
Speaker: Jeril Lasington, MD, MS, MBBS - New York Medical College at St.Mary's and St. Clare's, Denville -
03:00pm - 04:00pm ET
Prospective Quality of Life Outcomes after Stereotactic Body Radiotherapy for Hepatocellular Carcinoma in a Latin American Cohort
Speaker: Eugenio Vines, MD - Pontificia Universidad Catolica de Chile, Santiago -
03:00pm - 04:00pm ET
Preserving Function with Induction therapy: High Local Control Rates for Locally Advanced Anal Cancer
Speaker: Simran Polce, MD - Moffitt Cancer Center, Tampa -
03:00pm - 04:00pm ET
Uncovering Tumor Heterogeneity Captured by MRI-Based Radiomic Features across Clinical and Outcome Subgroups in Pancreatic Ductal Adenocarcinoma
Speaker: Xiangrong Qi, PhD - Dept. of Radiation Oncology, Los Angeles -
03:00pm - 04:00pm ET
Pretreatment Serum Lipidomics for Identifying Sarcopenia in Esophageal Cancer Patients Receiving Radiotherapy
Speaker: Jiahua Lv, MD, PhD - Sichuan Cancer Hospital and Institute, chengdu -
03:00pm - 04:00pm ETSpeaker: Federico Lorenzo, MD - RT International Institute, Montevideo
-
03:00pm - 04:00pm ETSpeaker: Sarah Finton, BA - David Geffen School of Medicine, Los angeles
-
03:00pm - 04:00pm ETSpeaker: Vincent Rothweiler, MD - Heinrich Heine University, Dusseldorf
-
03:00pm - 04:00pm ET
External Beam Radiotherapy for Gastroenteropancreatic Neuroendocrine Neoplasms: Long-Term Local Control, Survival and Toxicity
Speaker: Yuan Tang, MD - Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing -
03:00pm - 04:00pm ET
Organ Preservation-First Strategy Following Total Neoadjuvant Chemoradiotherapy for MRI-Defined Low-Risk Rectal Cancer: Early Results from a Prospective, Single-Center, Phase II Trial (PKUCH-R08)
Speaker: Lin Wang, MD - Peking University Cancer Hospital, Beijing